# Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

> **NCT05609942** · PHASE1 · TERMINATED · sponsor: **Blueprint Medicines Corporation** · enrollment: 9 (actual)

## Conditions studied

- Advanced Systemic Mastocytosis

## Interventions

- **DRUG:** BLU-263
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT05609942
- **Lead sponsor:** Blueprint Medicines Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-25
- **Primary completion:** 2025-01-14
- **Final completion:** 2025-03-10
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Terminated - alignment of strategic priorities
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05609942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05609942, "Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05609942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*